World Renal Cell Carcinoma Market to See Huge Changes in Years to Come, States GlobalData in Its Report Published at MarketPublishers.com05 Aug 2016 • by Natalie Aster
LONDON – Renal cell carcinoma (RCC) is amid the 10 most common types of cancer in Western nations. Presently, the RCC market is dominated by angiogenesis inhibitors and tyrosine-kinase inhibitors (TKIs) specifically, but it is likely to witness great changes in the years to come with patent expirations and promising novel therapies coming into the market. A number of large firms capture a formidable share of the RCC market, however, they are expected to struggle to maintain their shares as they are joined by new market entrants. Thus, new entrant Opdivo is likely to have the dominant market share by 2023-end. The various lines of therapy will offer up versatile battle fields and niches for both large and small firms to compete for. The battle for the first-line of treatment will likely be severe, with 3 programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)-enclosing multimodality therapies encouraged by large firms queueing up to compete. As a result of this competition, novel standards of care are anticipated to emerge for the various lines of ttherapy. A range of unmet needs are expected to remain in the foreseeable future, and there will likely be the opportunity for drugs in the pipeline to carve out a niche in the RCC market space.
Topical research report “PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023” created by GlobalData gives an exhaustive review of the RCC therapeutics marketplace.
The study reviews disease etiology, epidemiology, pathophysiology, diagnosis, symptoms, and therapy guidelines. It presents annualised market revenue, average cost of treatment and treatment usage pattern data starting from 2013 including forecasts to 2023. The research publication provides strategic competitor analysis, market characterisation, key unmet needs, clinical study mapping and implications for the market for RCC therapeutics. A granular pipeline assessment is included, comprising detailed data broken down across various phases, emerging new trends under development, and an all-round analysis of medications in late-stage development. Furthermore, the study sheds light on the market competition in the worldwide RCC therapeutics market, present-day and future. The report comprehensively examines major industry restraint, drivers, and challenges.
More reports by the publisher can be found at GlobalData page.